Background Sweat conductivity, which is equivalent to sweat NaCl concentration, is used as a screening test to identify possible cystic brosis (CF) patients. No data exist on the biological variation of this variable and the in uence it may have on the interpretation of sweat testing. The aim of this study was to determine the components of biological variation for sweat sodium chloride conductivity and to apply biological variation parameters in the interpretation of sweat conductivity.
Introduction
The high mortality of cystic ¢brosis (CF) focuses attention on the importance of a reliable diagnosis early in life so that appropriate medical treatment may be promptly initiated. The clinical features of CF are manifold, yet each symptom may di¡er greatly in degree of severity between patients. Furthermore, these features, when considered individually, are not speci-¢c for the disease. Consequently, de¢nitive diagnosis is di¤cult and depends heavily upon laboratory tests.
The United States Cystic Fibrosis Foundation (CFF) states that the diagnosis of CF is based on the following criteria: 1 1. The presence of one or more characteristic phenotypic features and/or a history of CF in a sibling;
2. Laboratory evidence of cystic ¢brosis transmembrane regulator (CFTR) abnormality as documented by elevated sweat chloride concen-tration, identi¢cation of two CF mutations located on chromosome 7q34, or demonstration of characteristic abnormalities in ion transport across the nasal epithelium.
The most widely used diagnostic method was ¢rst described by Gibson and Cooke in 1959 2 and involves the measurement of sodium or chloride in pilocarpine-stimulated sweat collected by adsorption on to pads. However, without care and scrupulous attention to detail, many sources of error or interference may give rise to misleading results. 3^5 Various alternative methods have been described, e.g. measurement of sweat chloride or sodium concentrations by a chloridometer or a £ame photometer, respectively, and the determination of sweat osmolality by a vapour-pressure osmometer. It is also possible to measure sweat conductivity, and to relate conductivity to sweat NaCl concentration. The Wescor Sweat-Check system (Wescor, Logan, Utah, USA) is such an analyser, and has been approved by the CFF for CF screening. 6
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All the above-mentioned techniques regularly produce equivocal results and these have always generated interest, if not frustration, among clinicians. Sometimes these results are laboratory artifacts, but equivocal results cannot always be ascribed to poor laboratory technique. CF is a disease that is known to express itself to a variable degree with respect to interference in organ function, and it is possible that this may also be the case with respect to eccrine secretory mechanisms.
The aim of this study was to determine the components of biological variation for sweat sodium chloride conductivity and to apply biological variation parameters in the interpretation of sweat conductivity results.
Methods and materials

Patient selection
Group 1 included 15 apparently healthy adult volunteers (hospital sta¡ ) with a median age of 31 years (range 20^40). Group 2 consisted of 20 healthy infants from a cre© che, with a median age of 12 months (range 2 months^24 months). Group 3 included 20 subjects known to have CF, with median age of 14 years (range 1^45). The diagnosis in this latter group was previously made by sweat testing, supported by assessment of malabsorption, family history and clinical course.
Patient protocol
Participants gave informed consent prior to enrolment in the study. In the case of minors (age 516 years), parents were required to give consent. The study was approved by the Human Ethics Committee of the University of Pretoria.
Sweat was collected from each participant by the Wescor Sweat-Check collection system for 30 min once a week for 5 consecutive weeks. The Wescor Sweat-Check system uses pilocarpine iontophoresis followed by sweat collection in a macroduct, a 4 cm (internal diameter) plastic device that ¢ts over the skin and is secured by Velcro straps. The sweat £ows into a small hole at the centre of the macroduct and into a microbore spiral plastic tube. Care was taken to ensure that the individuals were nutritionally and physiologically stable, well hydrated and not acutely ill. No subject was on corticoid replacement therapy. All sweat samples were analysed immediately after collection to eliminate conductivity changes due to evaporation.
Sweat conductivity determination
All the sweat samples were analysed for sweat sodium chloride conductivity using a Wescor Sweat-Check 3120 analyser. The instrument was used according to the manufacturer's instructions and was calibrated daily before any analyses were performed. The intact sweat was injected directly into the conductivity analyser. Because insu¤cient volumes of sweat were obtained, duplicate analyses could not be performed on all samples. Low, medium and high control material (Wescor), with assigned values of 40 mmoL/L, 72 mmoL/ L and 123 mmoL/L, respectively, were analysed in duplicate for 20 days to determine analytical imprecision. A constant bias of approximately 15 mmoL/L exists between sweat conductivity and sweat chloride concentration. 13 This di¡erence follows from a consideration of sweat electrolyte composition, that as the measurement of conductivity includes potassium, lactate and bicarbonate ions, the reference ranges for conductivity in terms of sodium and chloride standards are higher than those for sodium and chloride as such. 13 Despite this, the Wescor Sweat-Check analyser showed close agreement with the quantitative pilocarpine iontophoresis method of Gibson and Cook, 2 which has been accepted as the de-¢nitive method by the CFF. 6
Results
The between-run analytical variation (CV A ) was calculated separately for control samples in the low and high ranges. The within-subject variation (CV I ), the between-subject biological variation (CV G ) and the index of individualit y were calculated according to Fraser and Harris. 15 Table 1 shows the mean and range of sweat conductivity, as well as the analytical and biological components of variation as assessed by this study.
With the three components of variability (i.e. analytical imprecision, within-subject and between-subject variation) known, the total variability of a single measurement (CV T ) is given by:
The lower and upper limits of the 95% reference range are then calculated for each group by: mean § 2 SD, where SDˆCV T £ mean. The reference ranges are summariz ed in Table 1 .
Discussion
Patients with CF may have pulmonary manifestations in the presence of usual 18 or near-usual 19 sweat electrolyte concentrations. Elevated sweat electrolyte concentrations should be diagnostic, but a negative test does not exclude the possibility of CF. These ¢ndings may be explained by the heterogeneity of the disease and the variability of ¢F508 CFTR expression. 10 Post-translational events such as the e¤ciency of the folding, the half-life of the protein or cell type-spe-ci¢c protein targeting could likewise lead to the detected di¡erences of mutant CFTR expression. 8 This probably explains why de¢nitive results are not always obtained by sweat testing.
Fraser and Peterson 9 have shown that for parameters used to monitor decline in organ function, e.g. plasma creatinine, cardiac enzymes and urine microalbuminuria, the challenge is to detect signi¢cant changes in an individual whose results would still fall within the population reference range. By contrast, individuals with CF have a lifetime abnormality in sweat electrolyte secretion, rather than gradually declining function. The challenge here is to separate patients in whom CF can clearly be excluded from those requiring further investigation, without generating a large number of false positive results.
Our results support the recommendations of the Wescor manufacturers, that any conductivity result between 60 and 90 mmoL/L must be repeated by a de-¢nitive method (Wescor manufacturer's manual). By using the variability (analytical, within-subject and between-subject) around the mean, a suggested cut-o¡ value for repeat testing was calculated as 60 mmoL/ L (the upper limit for healthy babies). Furthermore, the lower limit of sweat conductivity in the CF group is 96 mmoL/L. This indicates that the Median values for the healthy participants are indicated by * and for the adults and infants, respectively, and by~for the CF subjects; the horizontal lines indicate the ranges. The vertical broken line indicates the CFF decision limit (50 mmol/L) for repeat con rmatory analyses, and the vertical solid line shows the manufacturers of the Wescor system's recommended decision limit for repeat testing (60 mmoL/L). range between 60 and 96 mmoL/L is an area of uncertainty where further laboratory tests are necessary.
In contrast, the CFF medical advisory committee set the decision limit at 50 mmoL/L. 6 The reason given for this lower decision limit was that a screening test may tolerate some false positive results in order to minimize or avoid false negative results. 6 However, it should be realized that repeat sweat conductivity testing may not be the answer to eliminating false positive results. Our study indicated that the intra-individual biological variation is small compared to the inter-individual biological variation, especially for healthy infants and adults. This low index of individuality (CV I /CV G ) indicates that repeat testing of positive results will tend to con¢rm positive results irrespective of whether these are true or false. 26, 27 Therefore, the use of arbitrarily de¢ned decision limits should be discouraged, as this may lead to unnecessary testing.
Admittedly, our study population is small and larger groups would have led to a more precise estimation of population means and reference ranges. However, the application of biological variation parameters to estimate reference ranges is useful in relatively uncommon conditions. Laboratories are encouraged to determine their own reference range. However, it is clearly unpractical for most laboratories to gather data on 120 CF patients in order to derive cut-o¡ points as recommended by the International Federation of Clinical Chemistry. 25 In our study, 40% of healthy infants would have been at risk of misdiagnosis with a cut-o¡ point of 50 mmoL/LCF. This would lead to further unnecessary testing, resulting in an increased ¢nancial and emotional burden for the patients. Only 16% had occasional positive results and required further testing if 60 mmoL/L was taken as the decision level. The adult control group demonstrated similar results (Fig. 1 ). In conclusion, our biological variation data support a sweat conductivity cut-o¡ point of 60 mmoL/L for further investigations in the screening for CF.
